• Voter paralysis

    With so much tilting voters against change, democratic reason is the loser, says Solly Moeng.

  • The power of perseverance

    True grit is a reliable predictor of who will achieve success in life, says Ian Mann.

  • It's the system

    The system sucks and it’s being used far too often as an excuse, says Mandi Smallhorne.

All data is delayed
Loading...
See More

Aspen boosts profit, Asian unit robust

Sep 12 2012 15:11
Reuters

Company Data

ASPEN PHARMACARE HOLDINGS LIMITED [JSE:APN]

Last traded 325
Change 6
% Change 2
Cumulative volume 624732
Market cap 0

Last Updated: 27-05-2016 at 05:00. Prices are delayed by 15 minutes. Source: McGregor BFA

ADCOCK INGRAM HOLDINGS LIMITED [JSE:AIP]

Last traded 42
Change 0
% Change 0
Cumulative volume 64910
Market cap 0

Last Updated: 27-05-2016 at 05:00. Prices are delayed by 15 minutes. Source: McGregor BFA

Related Articles

Aspen: Earning to between rise 18%-24%

Aspen unit to buy drug portfolio from GSK

Drug firms win R2.5bn tender

Aspen prepared to help bridge ARV shortages

Aspen buys GSK brands

Aspen buys GSK Aussie drugs for R2.2bn

 

Johannesburg - Drugs maker Aspen Pharmacare [JSE:APN] booked a 22% rise in full-year profit, helped by a robust showing in its Asia-Pacific unit.

Aspen, 19% owned by Britain GlaxoSmithKline, said in financial results released on Wednesday its normalised diluted headline earnings per share totalled 636.2 cents in the year to end-June compared with 523.3 cents a year earlier.

The biggest generic drugs maker in the southern hemisphere, Aspen is one of the companies most likely to benefit as some of best-selling name-brand drugs worth more than $100bn lose patent protection over the next three years.

Sales increased 23% to R15.3bn with its Asia-Pacific unit doubling its revenue to R6bn thanks to an acquisition.

Durban-based Aspen completed the acquisition of the generic business of Australia's Sigma Pharmaceuticals last year, boosting its presence in the region.

The company said it is looking to expand further in fast-growing Latin America, where it has small operations in Brazil, Venezuela and Mexico.

Shares in Aspen, which are up about 44% so far this year, were down 1.16% at R139.36, in line with its closest domestic rival Adcock Ingram Holdings [JSE:AIP], which was down 1.35% at R59.


*Follow Fin24 on Twitter, Facebook, Google+ and Pinterest.

 
aspen pharmacare holdings

NEXT ON FIN24X

 
 
 

Read Fin24’s Comments Policy

24.com publishes all comments posted on articles provided that they adhere to our Comments Policy. Should you wish to report a comment for editorial review, please do so by clicking the 'Report Comment' button to the right of each comment.

Comment on this story
0 comments
Comments have been closed for this article.
 

Company Snapshot

We're talking about:

THE DEBT ISSUE

Debt is one of the biggest financial issues facing South Africans today. Find out how you can avoid and manage your debt with Fin24 and Debt Rescue.
 

Money Clinic

Money Clinic
Do you have a question about your finances? We'll get an expert opinion.
Click here...

Voting Booth

Would you take out a payday loan?

Previous results · Suggest a vote

Loading...